Clinical Trial Update: A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) [Phase 3]

View source ↗

Summary

Phase 3 open-label study on long-term safety, tolerability, and efficacy of ambrisentan in inoperable chronic thromboembolic pulmonary hypertension was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thromboembolic Pulmonary Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2017-06-08